Ameriprise
GOSS icon

Ameriprise’s Gossamer Bio GOSS Stock Holding History

Ameriprise’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,426
Closed -$534K – 4111
2025
Q2 		$534K Buy
+5,426
New +$473K ﹤0.01% 3505
2024
Q1 		– Sell
-490
Closed -$35.7K – 3907
2023
Q4 		$35.7K Buy
+490
New +$29K ﹤0.01% 3860
2021
Q2 		– Sell
-383
Closed -$283K – 3918
2021
Q1 		$283K Sell
383
-13
-3% -$10.5K ﹤0.01% 3618
2020
Q4 		$307K Sell
396
-250
-39% -$197K ﹤0.01% 3498
2020
Q3 		$641K Buy
646
+310
+92% +$329K ﹤0.01% 3151
2020
Q2 		$350K Buy
336
+79
+31% +$79.5K ﹤0.01% 3309
2020
Q1 		$208K Sell
257
-6
-2% -$6.27K ﹤0.01% 3429
2019
Q4 		$329K Sell
263
-11
-4% -$17.7K ﹤0.01% 3454
2019
Q3 		$368K Sell
274
-536
-66% -$853K ﹤0.01% 3396
2019
Q2 		$1.44M Sell
810
-11
-1% -$16.8K ﹤0.01% 2916
2019
Q1 		$1.42M Buy
+821
New +$1.37M ﹤0.01% 2899

Other funds holding GOSS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ameriprise's GOSS Position: Q3 2025 in Review

Ameriprise sold out of Gossamer Bio (GOSS) in Q3 2025, closing a stake of 5,426 shares — an estimated $534K sold.

Ameriprise first reported a position in GOSS in Q1 2019 and held it in 11 quarters. The position peaked at $1.44M in Q2 2019. 162 funds tracked by Wall St. Rank hold GOSS as of Q3 2025.

  • Ameriprise reported no remaining Gossamer Bio position as of Q3 2025 after selling out during the quarter.
  • Ameriprise sold 5,426 Gossamer Bio shares in Q3 2025, an estimated $534K.
  • Ameriprise first reported a position in Gossamer Bio in Q1 2019 and held it in 11 quarters.
  • Ameriprise's Gossamer Bio position peaked at $1.44M in Q2 2019.
  • 162 funds tracked by Wall St. Rank held Gossamer Bio as of Q3 2025.

Based on Ameriprise's 13F filing for Q3 2025, filed 14 Nov 2025.